Paquinimod

Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice[1][2][3].

Product Specifications

CAS Number

[248282-01-1]

Product Name Alternative

ABR-215757; ABR 25757

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Paquinimod.html

Purity

99.90

Solubility

DMSO : 62.5 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C(O)C2=C(C=CC=C2CC)N(C)C1=O)N(CC)C3=CC=CC=C3

Molecular Formula

C21H22N2O3

Molecular Weight

350.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74 (12) :2254-8.|[2]Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13 (5) :e0196598.|[3]Qirui Guo, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. 2021 Feb 10;29 (2) :222-235.e4.